Replies to post #203907 on Amarin Corp Plc (AMRN)

[Invest83838]

I Like Fein's $51 per Share Price target

but one has to wonder how people like him become a biotech analyst

He really has no educational background in science or medicine

yet he is "the analyst" for biotech at Wainwright


"Mr. Fein is a Managing Director of Equity Research at H.C. Wainwright. Mr. Fein conducted more than twelve years of biotechnology equity research.
Prior to joining H.C. Wainwright, Mr. Fein worked as the Head of the Healthcare Research effort at Chardan Capital Markets. Mr. Fein began his career at J.P. Morgan H&Q and first gained recognition as a Senior Analyst at Leerink Swann. After that, Mr. Fein worked as a Managing Director/Senior Biotechnology Analyst at Jefferies, Piper Jaffray and Collins Stewart.
Mr. Fein has received numerous honorable mentions from the Institutional Investor All-America Research poll.
Mr. Fein’s educational background includes a Bachelor of Arts degree from Yale University."

[biotech_researcher]

H. C. Wainwright is really a third tier firm. Every one of their buy rating targets are 50% above the next highest it seems. Want the ultra bullish following I suppose..

[roadkilll]

AstraZeneca STRENGTH trial (Epanova) just updated and completion pushed back again. This time to Sept 2020 with readout some time after. (A big delay is not usually indicative of a strong positive outcome)

Epanova is a reformulated Lovaza with EPA/DHA and does a good job of lowering triglycerides. The CVOT outcome is a different animal and back in 2013 the FDA wouldn't approve the Vascepa label because of so much data showing EPA/DHA has not shown to improve CVOT outcomes.